Top Ranked Momentum Stocks to Buy for April 30th
Market forces rained on the parade of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shareholders today, when the analysts...
-- Conference Call Scheduled for Tuesday, May 5, 2020, at 8:30 a.m. ET -- NEWTON, Mass., April 28, 2020 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it.
Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 74,800 shares of Karyopharm’s common stock to 15 newly-hired employees, with a grant date of April 30, 2020. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $22.05 per share, the closing price of Karyopharm’s common stock on April 30, 2020.
Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a short period of time, companies with market caps of up to $10 billion are also found in the small cap universe.
Karyopharm (KPTI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -11.43% and -15.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced it will host an investor conference call to discuss detailed results from the pivotal, Phase 3 BOSTON study evaluating once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy. The conference call will follow the presentation of this data at the upcoming American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. As previously reported, the BOSTON study met its primary endpoint with a significant increase in progression-free survival in patients with multiple myeloma following one to three prior lines of therapy.
Large and small drug developers and academic researchers are furiously testing and hoping to find one or more treatments for COVID-19. While novel drugs aimed specifically at the coronavirus could potentially yield the greatest effects, the quickest route to a treatment might lie in repurposing existing drugs. Last week, Karyopharm Therapeutics (NASDAQ: KPTI) entered the fray of drug developers seeking to find solutions for those suffering from COVID-19.
Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today reported financial results for the quarter ended March 31, 2020. In addition, Karyopharm highlighted select corporate milestones, including details regarding the ongoing U.S. commercialization of XPOVIO® (selinexor), and provided an overview of its key clinical development programs.
Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for XPOVIO® (selinexor), its first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for patients with previously treated multiple myeloma. “Earlier this year, we reported positive top-line results from the pivotal Phase 3 BOSTON study evaluating the combination of XPOVIO (selinexor), once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) as a second line treatment for patients with relapsed or refractory multiple myeloma,” said Sharon Shacham, PhD, MBA, Founder, President and Chief Scientific Officer of Karyopharm.
Does Karyopharm Therapeutics (KPTI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Partners in Global COVID-19 Trial
KPTI earnings call for the period ending March 31, 2020.
NEWTON, Mass., May 12, 2020 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief.
Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 9:30 a.m. ET. A live webcast of the fireside chat can be accessed on the "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the fireside chat.
- A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study - NEWTON, Mass.,.
Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute 60,000 medical masks to some of the most vulnerable individuals impacted by the ongoing COVID-19 pandemic including cancer patients, their families, and the healthcare workers caring for them. Karyopharm will donate masks to Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society®, three prominent organizations focused on the well-being of cancer patients, to improve the safety and security of the broader cancer community. As part of this initiative, Family Reach, a national 501(c)(3) organization dedicated to eradicating the financial barriers that accompany a cancer diagnosis through their Financial Treatment Program, will distribute masks to hospitals throughout Massachusetts.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) fell 9% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 28.44% year over year to ($0.78), which missed the estimate of ($0.69).Revenue of $18,138,000 higher by 11601.94% from the same period last year, which missed the estimate of $21,280,000.Outlook Earnings guidance hasn't been issued by the company for now.Karyopharm Therapeutics hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: May 05, 2020View more earnings on KPTITime: 02:01 PM ETWebcast URL: https://edge.media-server.com/mmc/p/ogantstvRecent Stock Performance 52-week high: $29.6152-week low: $4.26Price action over last quarter: Up 23.60%Company Overview Karyopharm Therapeutics Inc is a pharmaceutical company. The company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer. Its pipeline products of the company include Oral Selinexor, Oral Eltanexor, Oral Dual Inhibitor of PAK4 and NAMPT and Oral Verdinexor, as well as its lead product, include XPOVIO.See more from Benzinga * PQ Group: Q1 Earnings Insights * Adient: Q2 Earnings Insights * Recap: Asbury Automotive Group Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.